8-K: Viemed Healthcare Completes $26 Million Acquisition of Lehans Medical Equipment, Anticipates Updated 2025 Guidance

Viemed Healthcare, Inc. has completed its previously announced acquisition of Lehans Medical Equipment for a base price of $26 million plus contingent consideration, and expects to update its full-year 2025 guidance to reflect the acquisition's contribution.

Summary

• Viemed Healthcare, Inc. completed the acquisition of Lehans Medical Equipment, a privately held provider of home medical equipment.
• The acquisition includes a base purchase price of $26 million, subject to customary adjustments, and estimated contingent consideration of approximately $2.2 million.
• Viemed funded the acquisition through a combination of cash on hand and borrowings from its existing credit facilities.
• Lehans Medical Equipment generated approximately $25.7 million in net revenues and $7.4 million in Adjusted EBITDA in 2024.
• Viemed anticipates updating its previously issued full-year 2025 guidance range to account for the expected contribution from this acquisition.
• The updated guidance will be provided when Viemed reports earnings results for the quarter ended June 30, 2025.
• Lehan offers home medical equipment and products for women's health, including breast pumps, and specializes in rental, sales, and resupply of CPAPs and other respiratory devices.
• Lehan operates three full-service locations in Northern Illinois and three sleep/CPAP setup locations in the West Chicagoland area, including one in Wisconsin.

Sentiment

Score: 8

Explanation: The document announces the successful completion of a strategic acquisition, which is expected to positively impact future financial guidance. It highlights the acquired company's strong track record and financial performance, indicating a beneficial expansion for Viemed.

Positives

• The acquisition of Lehans Medical Equipment expands Viemed's market presence and service offerings in a large and fast-growing market.
• Lehan brings an 80-year track record, strong brand recognition, preferred contracts, and fulfillment expertise.
• Lehan demonstrated strong financial performance in 2024, with $25.7 million in net revenues and $7.4 million in Adjusted EBITDA.
• The acquisition is expected to contribute positively to Viemed's full-year 2025 financial results, leading to an anticipated increase in guidance.
• Viemed utilized a combination of cash on hand and existing credit facilities to fund the acquisition, indicating financial flexibility.

Risks

• General business, market, and economic conditions in the regions of operation.
• Significant capital requirements and operating risks.
• Ability to implement business strategies and pursue business opportunities.
• Volatility in the market price of common shares.
• State of the capital markets and availability of funds and resources.
• Inflation.
• Reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities.
• Dependence on few payors.
• Possible new drug discoveries.
• Dependence on key suppliers.
• Granting of permits and licenses in a highly regulated business.
• Competition.
• Disruptions in or attacks (including cyber-attacks) on information technology, internet, network access or other voice or data communications systems or services.
• Evolution of various types of fraud or other criminal behavior.
• Difficulty integrating newly acquired businesses.
• Impact of new and changes to, or application of, current laws and regulations.
• Overall difficult litigation and regulatory environment.
• Increased funding costs and market volatility due to market illiquidity and competition for funding.
• Critical accounting estimates and changes to accounting standards, policies, and methods.
• Occurrence of natural and unnatural catastrophic events or health epidemics or concerns, and claims resulting from such events or concerns.

Future Outlook

Viemed anticipates increasing its previously issued full-year 2025 guidance range to account for the expected contribution from the Lehan acquisition. This updated guidance will be provided when the company reports its earnings results for the quarter ended June 30, 2025.

Management Comments

• "We are pleased to close the acquisition of Lehan and bring this talented and highly motivated team into the Viemed family." Casey Hoyt, Chief Executive Officer.
• "Lehans 80-year track record and brand recognition in a large and fast-growing market along with its preferred contracts and fulfillment expertise make for a powerful combination with our national scale, unique care delivery model and existing payer relationships to serve a broader patient population." Casey Hoyt, Chief Executive Officer.

Industry Context

The acquisition of Lehans Medical Equipment by Viemed Healthcare highlights a trend towards consolidation and expansion within the in-home clinical care and home medical equipment (HME) sector. As healthcare shifts towards more decentralized, patient-centric models, providers like Viemed are strategically acquiring established regional players to expand geographic reach, diversify service offerings (e.g., women's health, sleep therapy), and leverage existing payer relationships and brand recognition. This move positions Viemed to capture a larger share of the growing post-acute respiratory healthcare and general HME market, aligning with broader industry efforts to provide comprehensive care in patients' homes.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to assess Viemed's acquisition in the context of global benchmarks.
• The acquisition of a company with an 80-year track record and significant regional brand recognition, generating $25.7 million in net revenues and $7.4 million in Adjusted EBITDA in 2024, suggests a strategic move to acquire an established and profitable entity within the home medical equipment sector.
• The stated purchase price of $26 million plus $2.2 million contingent consideration relative to Lehan's 2024 Adjusted EBITDA of $7.4 million implies an acquisition multiple of approximately 3.5x to 3.8x Adjusted EBITDA (excluding contingent consideration, it's ~3.5x; including it, it's ~3.8x). This multiple is generally within the range for acquisitions in the healthcare services and HME space, which can vary widely based on growth prospects, market position, and specific service lines.
• Without direct comparables, it is difficult to definitively benchmark this specific transaction against industry averages, but the acquisition of a profitable, established entity is a common strategy for growth in this fragmented market.

Stakeholder Impact

• Shareholders: Expected positive impact on future financial guidance and potential for increased share value due to expanded market presence and revenue growth.
• Employees: Lehan's "talented and highly motivated team" is being integrated into the Viemed family, suggesting continued employment and potential new opportunities within a larger organization.
• Customers/Patients: Expanded service offerings and geographic reach, potentially leading to broader access to in-home clinical care and medical equipment.
• Suppliers: Potential for increased volume or new relationships as Lehan's operations integrate with Viemed's national scale.

Next Steps

• Viemed will report earnings results for the quarter ended June 30, 2025.
• Viemed will update its full-year 2025 guidance to reflect the expected contribution from the Lehan acquisition.

Key Dates

Recommendation

Keywords

Viemed Healthcare, Lehans Medical Equipment, acquisition, home medical equipment, HME, respiratory healthcare, post-acute care, non-invasive ventilators, NIV, sleep therapy, CPAP, healthcare services, M&A, financial guidance, SEC filing, 8-K